BDRX - Biodexa Pharmaceuticals Plc
4
-0.330 -8.250%
Share volume: 68,815
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$4.33
-0.33
-0.08%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
14.94%
1 Month
484.80%
3 Months
84.33%
6 Months
-40.74%
1 Year
185.71%
2 Year
422.88%
Key data
Stock price
$4.00
DAY RANGE
$3.75 - $4.28
52 WEEK RANGE
$0.60 - $11.88
52 WEEK CHANGE
$181.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
Company detail
CEO: Stephen A. Stamp
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Midatech Pharma plc focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. MTX114, an immuno-suppressant for topical application in psoriasis, MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder.
Recent news